Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26048243
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Repurposing medicinal compounds for blood cancer treatment
#MMPMID26048243
McCabe B
; Liberante F
; Mills KI
Ann Hematol
2015[Aug]; 94
(8
): 1267-76
PMID26048243
show ga
Drug development is being continuously scrutinised for its lack of productivity.
Novel drug development is associated with high costs, high failure rates and
lengthy development process. These downfalls combined with a huge demand in blood
cancer for new therapeutic treatments have led many to consider the method of
drug repurposing. Finding new therapeutic indications for already established
drug substances is known as redirecting, repositioning, reprofiling, or
repurposing of drugs. Off-patent and on-patent drugs can be screened for
additional targets and new indications thus bringing them to clinical trials at a
faster pace. This approach offers smaller research groups, such as those that are
academic based, into the drug development industry. Drug repurposing can make use
of previously published data concerning dosage, toxicology and mechanism of
activity.
free
free
free
